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similar for patients with NIDDM and non-diabetics. Clinically driven
TVR was 5.97% for diabetics and 3.38% for non-diabetic patients.
Deﬁnite or probable ST occurred in 0.9% for diabetic and non-diabetic
patients, and in 1.0% of patients with IDDM.
CONCLUSIONS In this registry, diabetic patients receiving a Biolimus
A9–eluting DES had a signiﬁcantly higher rate of MACE than non-
diabetics, but similar and low rates of ARC deﬁnite or probable stent
thrombosis at 3 y of follow up.
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BACKGROUND The e-Biomatrix registry is a prospective, multi-
center, observational registry investigating the long-term clinical
events after treating a “real world, all-comers” patient population
with either BioMatrix or BioMatrix Flex stents. This BA9-
eluting stent (BES) has an abluminal biodegradable polymer coating,
which disappears within 9 months, and is intended to prevent the
late events that may be associated with the existence of durable
polymer. This work presents the inﬂuence of comorbidities on out-
comes in this setting. We present the ﬁnal result of our study on the
impact of comorbidities (using the Charlson’s comorbidity index) on
clinical outcomes.
METHODS We used the Charlson comorbidity index (CCI), a scoring
system involving weighting factors on the basis of disease severity,
including cardiovascular diseases, diabetes, renal failure, chronic
infections and malignant tumors. Among 5472 patients in this reg-
istry, 2953 (54%) had at least one comorbidity, of which the most
common comorbidities were prior myocardial infarction (24.9% of
the population), diabetes mellitus (24.1%), peripheral vascular dis-
ease (6.8%), congestive heart failure (5.2%), chronic obstructive
pulmonary disease (5.2%), cerebral vascular disease (5.7%) and renal
failure (2.7%). Four patient subgroups with Charlson comorbidity
indices equal to 0, 1, 2, and 3 are deﬁned as follows: CCI-0 (no
comorbidity; n¼ 2517), CCI-1 (CCI¼1; n¼1709), CCI-2 (CCI¼2; n¼694),
CCI3 (n¼550). With increasing CCI, patients were older, had higher
rates of hypertension, hypercholesterolemia, and obesity, but were
less often current smokers. They had undergone increasingly often a
prior PCI or CABG and had more often decreased LV ejection frac-
tion. LVEF <40%: CCI-0: 4.78%, CCI-1: 6.5%, CCI-2: 14.19%, CCI3:
28.1%; p<0.01. Compared to the other groups, patients with CCI3
underwent PCI less often for STEMI (CCI-0: 41.7%, CCI-1: 30.3%,
CCI-2: 25.7%, CCI3: 13.8%).
RESULTS At 1 year, the comparison of the subgroups by the Kaplan-
Meier curves suggested a direct correlation between CCI and MACE,
but not between CCI and bleeding or stent thrombosis. However, in a
multivariate analysis CCI was shown to be no longer an independent
predictor of MACE. The ﬁnal 36-months data including the primary
endpoint (MACE), Mortality, MI, stent thrombosis and bleeding, is in
the process of being analyzed and will be reported at the time of
presentation. Furthermore, the results of the multivariate analysis
will be reported to identify the independent predictors of 36-month
mortality, MACE, and major bleeding.
CONCLUSIONS This large international study demonstrates the
impact of comorbidities on long-term safety and efﬁcacy outcomes in
patients undergoing PCI. The complete ﬁnal 3-year follow-up analysis
will be available at the time of the meeting.
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BACKGROUND A post marketing clinical follow-up study was
conducted evaluating the continued safety and effectiveness of the
CE-mark approved DESyne Novolimus Eluting Coronary Stent
System (NECSS) (Elixir Medical, Sunnyvale, CA), a Co-Cr stent with
a durable biocompatible polymer and Novolimus, a macrocyclic
lactone mTOR inhibitor. The drug dose is 5 mg per mm of stent
length.
METHODS A total of 57 patients were enrolled into the EXCELLA Post-
marketing Clinical Follow-up (PMCF) study. All were treated with the
DESyne NECSS for de novo lesions in native coronary arteries with a
reference vessel diameter between 2.5 and 4.0mm treatable with
stents between 14 and 38 mm in length. Patient data were analyzed
for the clinical endpoints of major adverse cardiac events (MACE)
deﬁned as: cardiac death, target vessel MI, clinically-indicated target
lesion revascularization (TLR); target vessel revascularization and
stent thrombosis at 1, 9, 12 and 24 months. The study was approved
the local Ethics Committees and all patients provided informed
consent.
RESULTS Patients were enrolled between February 2014 and May
2014, in Germany, Jordan and Spain. After the index procedure, pa-
tients were contacted at 1, 9 and 12 months either via an ofﬁce visit or
telephonically. The mean age of patients was 62 years; 38.6% were
diabetics and 72% presented with hypercholesterolemia and 72% with
hypertension and 12.3% had unstable angina. Baseline lesion charac-
teristics revealed 51% type C lesion with a mean reference vessel
diameter of 2.84  0.45mm and lesion length of 17.27  8.73mm.
Clinically, the DESyne NECSS demonstrates excellent safety with no
clinical events reported through 30 days and continued low MACE
rates through 12 months; with the full demographic, lesion and clin-
ical data through 12 months to be presented.
CONCLUSIONS The DESyne NECSS continues to demonstrate excel-
lent clinical safety similar to the clinical safety results seen in the
pivotal EXCELLA II Randomized Study. Demographic and clinical re-
sults through 12 months will be presented.
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BACKGROUND The Resolute IntegrityTM zotarolimus-eluting stent
(ZES; Medtronic, Inc.) is designed with a single continuous wire
formed into a repeating sinusoidal pattern (as compared with discrete
rings with the previous Resolute ZES) with the goal to enhance
deliverability. The objective of RESOLUTE INTEGRITY US Zotar-
olimus-Eluting Coronary Stent System Clinical Study is to investigate
outcomes with Resolute Integrity ZES.
METHODS The RESOLUTE INTEGRITY US study is a multi-center,
single-arm, open label study in the United States that enrolled pa-
tients with de novo lesions with length 30 mm and vessel diameter
of 2.25 to 4.2 mm. Clinical outcomes have not been previously re-
ported. Patients will have been followed for two years by the time of
TCT 2015.
RESULTS The RESOLUTE INTEGRITY US study enrolled 230 patients
(251 lesions); 42% had diabetes mellitus, including 17% with insulin-
dependent diabetes mellitus, 24% prior myocardial infarction, 83% of
